Ophthotech Announces Results from Third Phase 3 Trial of Fovista® in Wet Age-Related Macular Degeneration
NEW YORK--(BUSINESS WIRE)--Ophthotech today announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved.